- Home
- OTLK vs ICCM Comparison
OTLK vs ICCM Comparison
Compare OTLK & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | ICCM |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.8M | 45.5M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | ICCM |
|---|---|---|
| Price | $2.06 | $0.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $5.25 | $2.50 |
| AVG Volume (30 Days) | ★ 5.5M | 403.0K |
| Earning Date | 12-26-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,505,322.00 | ★ $2,975,000.00 |
| Revenue This Year | N/A | $13.67 |
| Revenue Next Year | $342.80 | $38.55 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.79 | $0.59 |
| 52 Week High | $3.39 | $1.66 |
Technical Indicators
Market Signals| Indicator | OTLK | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 69.44 | 41.99 |
| Support Level | $1.51 | $0.67 |
| Resistance Level | $2.10 | $0.72 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 93.22 | 62.50 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.